Compare
Collegium Pharmaceutical vs Merck & (COLL vs MRK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Collegium Pharmaceutical (COLL) returned -32.5% and Merck & (MRK) +73.9%; so far this year the figures are -47.7% and +39.4%.
Merck & is the larger company by market value, about 482.3 times the size of Collegium Pharmaceutical.
On trailing earnings, COLL trades at 24.2 times and MRK at 149.7 times.
Revenue grew +7.7% at COLL and +4.9% at MRK over the last year.
COLL pays no dividend. MRK yields 2.32%.
Data as of the latest close. Not investment advice.
Relative performance
| COLL | MRK | |
|---|---|---|
| Price | $24.21 | $146.73 |
| 1-day | -3.78% | -0.14% |
| YTD | -47.71% | +39.40% |
| 1 year | -32.47% | +73.87% |
| 3 years | +11.06% | +42.66% |
| Market cap | $750M | $361.7B |
| P/E | 24.2 | 149.7 |
| P/S | 0.92 | 5.37 |
| P/B | 2.54 | 8.06 |
| Revenue growth | +7.70% | +4.90% |
| EPS growth | -37.90% | -87.10% |
| Gross margin % | 59.0 | 71.8 |
| Net margin % | 4.7 | 3.6 |
| ROE % | 12.9 | 5.5 |
| Debt / equity | 0.05 | 1.20 |
| FCF yield % | 44.7 | 4.1 |
| Dividend yield % | — | 2.32 |
| Beta | 0.11 | 0.18 |
| RSI (14) | 56.8 | 51.3 |
| Technical rating |